Sugi Predict

Sugi Predict / Compounds / SCHEMBL15440

SCHEMBL15440

SCHEMBL15440

CC(C)/C=C(\C#N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.42
▸ CISD1 Q9NZ45 1/20 0.42
▸ SLC16A3 O15427 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ SLC16A1 P53985 1/20 0.42
▸ GPR35 Q9HC97 1/20 0.42
▸ EGFR P00533 3/20 0.38
▸ LMNA P02545 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ GRIK1 P39086 1/20 0.35
▸ GRIA2 P42262 1/20 0.35
▸ GRIA4 P48058 1/20 0.35
▸ GRIK3 Q13003 1/20 0.35
▸ GRIK5 Q16478 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22246044 1.00 KDM4E (0.42) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL15441 1.00 KDM4E (0.42) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL11051248 0.84 KDM4E (0.41) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL541123 0.82 KDM4E (0.40) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
Morpholine SCHEMBL28457676 0.81 KDM4E (0.33) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL16646930 0.81 EGFR (0.32) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL13696929 0.80 KDM4E (0.39) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL448846 0.80 KDM4E (0.39) KDM4ECISD1SLC16A3ALDH1A1CYP3A4
SCHEMBL11386792 0.79 EGFR (0.45) KDM4EALDH1A1CYP3A4HPGDEGFR
SCHEMBL20847037 0.79 EGFR (0.31) ALDH1A1EGFRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710458-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-10-30 — — US disclosed
EP-3181567-B9 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2025-09-24 — — EP disclosed
US-12312370-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-05-27 — — US disclosed
US-20240199655-A1 Immunoproteasome Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-06-20 — — US disclosed
US-20240174676-A1 Pyrazolopyrimidine compounds as kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-05-30 — — US disclosed
CN-111491938-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2024-05-24 — — CN disclosed
US-11827656-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2023-11-28 — — US disclosed
US-11827656-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2023-11-28 — — US disclosed
EP-3445812-B1 REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS AND FILMS MADE THEREFROM EASTMAN CHEM CO (US) 2023-10-25 — — EP disclosed
US-6620829-B2 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt WARNER-LAMBERT COMPANY 2003-09-16 — — US disclosed
WO-2003063845-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY LLC (US) 2003-08-07 — — WO disclosed
US-20020072533-A1 Method of treating cartilage damage SCHRIER DENIS (US) 2002-06-13 — — US disclosed
EP-1199072-A2 Method of treating cartilage damage WARNER-LAMBERT COMPANY (US) 2002-04-24 — — EP disclosed
EP-1192125-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076958-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed
EP-0609371-B1 THIENOPYRAZINE-2,3-DIONES USEFUL FOR TREATING CNS DISORDERS, AND THEIR PREPARATION. NOVO NORDISK AS (DK) 1996-04-24 — — EP disclosed
EP-0609371-A1 THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE. NOVO NORDISK AS (DK) 1994-08-10 — — EP disclosed
US-5284847-A Neurological and psychological disorders; antagonist at the glycine binding site on the N-methyl-D-aspartate receptor complex NOVO NORDISK A/S (DK) 1994-02-08 — — US disclosed
WO-1993008197-A1 THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1993-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827656-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 KDM4E 1084/4885CISD1 3827/4885SLC16A3 4600/4885
US-20240199655-A1 Immunoproteasome Inhibitors PSMC2, PSMB7, PSMB2 KDM4E 1084/4885CISD1 3827/4885SLC16A3 4600/4885
US-20020072533-A1 Method of treating cartilage damage COL2A1, COL1A1, GABRB1 KDM4E 3350/4885CISD1 2423/4885SLC16A3 262/4885
US-12312370-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 KDM4E 1084/4885CISD1 3827/4885SLC16A3 4600/4885
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL KDM4E 3651/4885CISD1 3050/4885SLC16A3 4196/4885
US-20240174676-A1 Pyrazolopyrimidine compounds as kinase Inhibitors BTK, LCK, LYN KDM4E 1198/4885CISD1 3282/4885SLC16A3 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.